1) 三浦靖史, 他:関節リウマチ患者へのインフリキシマブ点滴時間は1時間に短縮可能である. 日関節病会誌 28:515-519, 2009
2) Imafuku S, et al.: Remission of anti-tumor necrosis factor-a antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis. J Dermatol 48:e240-e241, 2021
3) Imafuku S, et al.: Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis. Br J Dermatol 166:675-678, 2012
4) Imafuku S, et al.: Cutaneous pseudolymphoma caused by tumor necrosis factor- α inhibitors was not induced by ustekinumab. J Dermatol 39:1070, 2012
5) Oiso N, et al.: Renbok phenomenon in a patient with alopecia areata universalis and psoriasis. J Dermatol 39:288-289, 2012
6) Tauber M, et al.: Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70:1146-1149, 2014
7) Armagan BY, et al.: New onset alopecia areata during secukinumab therapy. Dermatol Ther 32:e13071, 2019
8) S lowinska M, et al. Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep 4:15-17, 2010
9) Tauber M, et al.: Alopecia areata developing during ustekinumab therapy: report of two cases. Eur. J Dermatol 23:912-913, 2013.
10) Eldirany SA, et al.: Ixekizumab-induced alopecia areata. JAAD Case Rep 6:51-53, 2019
11) Kuwatsuka S, et al.: Bright side of biologics uncovered the dark side of long-term topical steroids: A psoriatic patient treated with biologics developed severe adrenal crisis. J Dermatol 47:e307-e308, 2020
12) 相原道子.薬疹up-to-date 薬疹の最近の話題.日臨皮医誌 30:162, 2013
13) 新川衣里子, 他:ニボルマブ投与後の他剤による薬疹の検討.日皮会誌 128:2109-2116, 2018.
14) Burla J, et al.: Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis:Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflamm Intest Dis 5:109-116, 2020
15) Tanaka R, et al.: Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. J Dermatol Sci 86:71-73, 2017
16) 沖山奈緒子, 他:免疫チェックポイント阻害剤によって誘発される多彩な自己免疫反応性副作用-interleukin-6を介する乾癬様皮膚炎を中心に-.日臨免疫会誌 40:95-101, 2017
17) Blauvelt A, et al.: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS):a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287-2303, 2017
18) Wollenberg A, et al.: Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials(ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437-449, 2021
19) Jo CE, et al.: Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol 84:1339-1347, 2021